Bristol Myers radiopharma cancer drug slows rare tumor progression in study | Reuters

Bristol Myers experimental drugs show promise in late-stage lung disease and cancer trials

Bristol Myers Squibb reported positive results from late-stage trials of experimental drugs for treating a rare endocrine cancer and idiopathic pulmonary fibrosis, with the radiopharmaceutical therapy significantly delaying disease progression in gastrointestinal and pancreatic tumors.